UBS raised the firm’s price target on HCA Healthcare (HCA) to $525 from $495 and keeps a Buy rating on the shares. The firm surveyed 150 health benefit managers across the country to gain insight and perceptions around national health insurance companies, cost trends and premium expectations, along with priorities with respect to health benefit design for 2026, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $520 from $470 at Goldman Sachs
- HCA Healthcare price target raised to $425 from $400 at Morgan Stanley
- HCA Healthcare price target raised to $525 from $444 at Cantor Fitzgerald
- HCA Healthcare price target raised to $500 from $400 at Oppenheimer
- HCA Healthcare price target raised to $505 from $475 at Mizuho